JCJanet L. Crane

Janet L. Crane

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Janet L. Crane has a total of 304 co-authors. Here are the top co-authors by number of shared publications:

  • Xu Cao

    Department of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, USA

    21 shared publications
  • Mei Wan

    Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

    13 shared publications
  • Xu Cao

    Department of Orthopedic Surgery, Johns Hopkins University School of Medicine, Baltimore, USA

    12 shared publications
  • Gehua Zhen

    Department of Orthopedic Surgery The Johns Hopkins University School of Medicine Baltimore MD USA

    11 shared publications
  • Mei Wan

    Department of Orthopaedic Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

    10 shared publications
  • Liang Xie

    Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD USA

    7 shared publications

Latest Publications

  • Open Access

    Managing growth and puberty concerns in individuals with Duchenne muscular dystrophy: Updated guidance and future directions

    by Meilan M. Rutter, Janet L. Crane, Funmbi Babalola, Robert W. Benjamin, Carol Lam, Laura McAdam, Stefan Nicolau, Anne Marie Sbrocchi, Mena Scavina, Julia Sorbara, et al.

    Long-term glucocorticoid therapy is standard of care for individuals with Duchenne muscular dystrophy (DMD) but often results in impaired growth and delayed or incomplete puberty, impacting their physical and psychosocial health. Although DMD endocrine care has evolved, leading to inclusion in the 2018 Care Considerations, these issues remain prevalent and concerning, and gaps in care persist. The Growth and Puberty Working Group of the OPTIMIZE DMD Consortium, an international multidisciplinary group including endocrinology and neuromuscular specialists with DMD expertise, conducted a literature review and surveyed clinicians to inform updated clinical guidance on growth and puberty. This report is based on evidence where available, plus expert consensus, and thereby provides revised guidance on the investigation and management of growth and pubertal delay, as well as hypogonadism beyond the pubertal years, among individuals with DMD. It also addresses new topics subsequent to the 2018 Care Considerations, including: 1) the dissociative glucocorticoid vamorolone and its impact on growth, and 2) gonadal function in older adolescents and young adults. With the current lack of long-term data on growth and puberty outcomes, prevailing themes underscore the importance of person- and family-centered care with informed shared decision-making aligned with individualized goals plus interdisciplinary team communication. This report also highlights specific areas in these domains in need of research. Through ongoing collaborations within the OPTIMIZE DMD Consortium, growth and puberty care continues to evolve and will inform and advance research to improve the health and quality of life of individuals with DMD.

  • Open Access

    Hypothalamic prolactin receptor+ dopaminergic neurons regulate energy metabolism and nociceptive threshold in mice during lactation

    by Ningrong Chen, Shreya Kumar, Kalp Patel, Shangqing Li, Mei Wan, Janet Crane, Xu Cao

    Women during lactation undergo significant bone loss and metabolic changes. However, the underlying mechanisms in the brain remain unclear. Herein, we found that prolactin receptor (PRLR)+ neurons in the hypothalamus control lactation physiology and metabolism in mice. Prolactin induces tyrosine hydroxylase (Th) expression in PRLR+ dopaminergic neurons of the arcuate nucleus (ARC). Interestingly, neuropeptide Y (NPY) expression was elevated to alter energy demand and nociceptive threshold during lactation. Knocking down either PRLR or NPY in the ARC significantly reduced food demand and nociceptive threshold. Importantly, in addition, prolactin also induces Th expression in the hypothalamic paraventricular nucleus (PVN) to increase sympathetic outflow to mobilize Ca2+ in bone. Importantly, brain-derived osteoanabolic hormone communication network factor 3 (CCN3) is downstream of PRLR signaling in the dopaminergic neurons. Thus, hypothalamic PRLR+ neurons identified in the current study regulate bone and fat metabolism, nociceptive threshold, and energy demand in mice during lactation.

  • Open Access

    PTH induced osteoblast Slit3 to decrease aberrant sensory innervation in degenerated vertebral endplates to relieve low back pain in mice

    by Weixin Zhang, Arryn D. Otte, Zhuolun Wang, Sisir Kumar Barik, Mei Wan, Xu Cao, Janet L. Crane

    During aging, the spine undergoes degenerative changes, particularly with vertebral endplate bone expansion and sclerosis, that are associated with nonspecific low back pain. We report that parathyroid hormone (PTH) treatment reduced vertebral endplate sclerosis and improved pain behaviors in three mouse models of spinal degeneration (aged, SM/J, and young lumbar spine instability mice). Aberrant innervation in the vertebral body and endplate during spinal degeneration was decreased with PTH treatment as quantified by PGP9.5 + and CGRP + nerve fibers, as well as CGRP expression in dorsal root ganglia. The neuronal repulsion factor Slit3 significantly increased in response to PTH treatment mediated by transcriptional factor FoxA2. PTH type 1 receptor and Slit3 deletion in osteocalcin-expressing cells prevented PTH-reduction of endplate porosity and improvement in behavior tests. Altogether, PTH stimulated osteoblast production of Slit3, decreased aberrant sensory nerve innervation, and provided symptomatic relief of LBP associated with mouse spinal degeneration.


  • Glucocorticoid-induced osteoporosis in children: emerging vascular and molecular targets

    by Sisir Kumar Barik, Janet L. Crane

    Purpose of review: Glucocorticoid-induced osteoporosis (GIO) poses a significant risk to pediatric patients undergoing chronic glucocorticoid therapy for inflammatory, autoimmune, and genetic conditions. This review highlights the pathophysiology of GIO in children and emerging insights into the role of bone vasculature in skeletal health during growth. Recent findings: GIO arises from a dual mechanism of increased bone resorption and decreased bone formation, leading to rapid declines in bone mineral density. Recent studies emphasize the importance of angiogenic-osteogenic coupling, particularly in the growing skeleton. Endothelial cells are now recognized as active participants in bone health and regeneration. Advances in the understanding of signaling pathways regulating skeletal angiogenesis could predict skeletal side effects during drug development. Therapies enhancing endothelial cell function or promoting skeletal angiogenesis could mitigate glucocorticoid-induced damage. Key signaling pathways, such as platelet-derived growth factor type BB and nuclear factor (NF)-κB play critical roles in recruiting osteoprogenitors and establishing a vascular niche for skeletal angiogenesis. Summary: GIO is uniquely concerning in children due to its impact on peak bone mass and lifelong fracture risk. Understanding how glucocorticoids impair bone vasculature and skeletal remodeling may reveal new therapeutic targets to preserve bone health and mitigate the osteotoxic effects of long-term glucocorticoid use in the growing skeleton.


  • Open Access

    Circulating CD34-positive cells are associated with prolonged time to fracture in people with Duchenne muscular dystrophy on chronic glucocorticoids

    by Angela Sadlowski, Julia See, Sonum Bharill, Weixin Zhang, Arryn Otte, Emely Loscalzo, Nazanin Yousefzadeh, Ethan Gough, Tricia Nilles, Sisir Barik, et al.

    Glucocorticoids decrease preosteoclast (POC) platelet-derived-growth-factor-type-BB (PDGF-BB), reducing migration of endothelial and osteo-progenitor cells, impairing skeletal angiogenesis and osteogenesis in mice. To explore human translation, we conducted a case–control study on Duchenne muscular dystrophy (DMD) youth treated with chronic glucocorticoids (n=24) relative to healthy controls (n=13) to explore the association of PDGF-BB, VEGF, angiogenin concentration and peripheral blood mononuclear cell (PBMC) subpopulations as surrogates of POCs (CD14+/Stro-1−/CD105−), skeletal progenitor cells (SPCs: Stro-1+/CD105+/CD14−/CD45−), and endothelial/hematopoietic progenitor cells (CD34+/CD14-/Stro-1−/CD105−) and CE140b mean fluorescence intensity (MFI) to fracture. People with DMD (8-20 years), were stratified by prior and subsequent fractures relative to biospecimen collection. Healthy controls were age- and sex-matched. Differences between groups were assessed with one-way ANOVA with post-hoc Tukey’s test, retrospective fractures by Kendall Tau correlation, and prospective fractures by bivariable and multivariable accelerated time failure models. Baseline characteristics between groups were similar, though people with DMD were shorter relative to healthy controls, and in the DMD groups, those with prior fractures had a longer duration of glucocorticoid therapy. We noted decreased PDGF-BB concentration and percentages of circulating POCs, SPCs, and CD34+ cells in people with DMD relative to healthy controls. Circulating CD34+ cell percentage positively correlated with PDGF-BB concentration, similar to murine models. Lower percentage of circulating SPCs and CD140b MFI was associated with increased number of retrospective fractures. After a mean follow-up of 2.23 yr, 79% of people with DMD sustained a subsequent fracture. Higher PDGF-BB concentration and percent of POC, SPCs, and CD34+ cells were associated with a longer time to next fracture. After controlling for covariates of fracture risk, increased percentage of CD34+ cells continued to be associated with prolonged time to fracture. Circulating CD34+ cells may thus be a potential biomarker to predict acute fracture risk in young people with DMD on chronic glucocorticoids.


  • Open Access

    Slit3 by PTH-Induced Osteoblast Secretion Repels Sensory Innervation in Spine Porous Endplates to Relieve Low Back Pain

    by Janet Crane, Weixin Zhang, Arryn Otte, Sisir Barik, Mei Wan, Xu Cao

    During aging, the spine undergoes degenerative changes, particularly with vertebral endplate bone expansion and sclerosis, that is associated with nonspecific low back pain (LBP). We reported that parathyroid hormone (PTH) treatment could reduce vertebral endplate sclerosis and improve pain behaviors in aging, SM/J and young lumbar spine instability (LSI) mice. Aberrant innervation noted in the vertebral body and endplate during spinal degeneration was reduced with PTH treatment in aging and LSI mice as quantified by PGP9.5+ and CGRP+ nerve fibers, as well as CGRP expression in dorsal root ganglia (DRG). The neuronal repulsion factor Slit3 significantly increased in response to PTH treatment mediated by transcriptional factor FoxA2. PTH type1 receptor (PPR) and Slit3 deletion in osteoblasts prevented PTH-reduction of endplate porosity and improvement in behavior tests, whereas PPR deletion in chondrocytes continued to respond to PTH. Altogether, PTH stimulates Slit3 to repel sensory nerve innervation and provides symptomatic relief of LBP associated with spinal degeneration.


  • Parathyroid hormone treatment partially reverses endplate remodeling and attenuates low back pain in animal models of spine degeneration

    by Zemin Ling, Janet Crane, Hao Hu, Yan Chen, Mei Wan, Shuangfei Ni, Shadpour Demehri, Bahram Mohajer, Xinsheng Peng, Xuenong Zou, et al.

    Low back pain (LBP) is one of the most prevalent diseases affecting quality of life, with no disease-modifying therapy. During aging and spinal degeneration, the balance between the normal endplate (EP) bilayers of cartilage and bone shifts to more bone. The aged/degenerated bony EP has increased porosity because of osteoclastic remodeling activity and may be a source of LBP due to aberrant sensory innervation within the pores. We used two mouse models of spinal degeneration to show that parathyroid hormone (PTH) treatment induced osteogenesis and angiogenesis and reduced the porosity of bony EPs. PTH increased the cartilaginous volume and improved the mechanical properties of EPs, which was accompanied by a reduction of the inflammatory factors cyclooxygenase-2 and prostaglandin E 2 . PTH treatment furthermore partially reversed the innervation of porous EPs and reversed LBP-related behaviors. Conditional knockout of PTH 1 receptors in the nucleus pulposus (NP) did not abolish the treatment effects of PTH, suggesting that the NP is not the primary source of LBP in our mouse models. Last, we showed that aged rhesus macaques with spontaneous spinal degeneration also had decreased EP porosity and sensory innervation when treated with PTH, demonstrating a similar mechanism of PTH action on EP sclerosis between mice and macaques. In summary, our results suggest that PTH treatment could partially reverse EP restructuring during spinal regeneration and support further investigation into this potentially disease-modifying treatment strategy for LBP.


  • Open Access

    Growth hormone and testosterone delay vertebral fractures in boys with muscular dystrophy on chronic glucocorticoids

    by Emely Loscalzo, Julia See, Sonum Bharill, Nazanin Yousefzadeh, Ethan Gough, Malinda Wu, Janet L. Crane

    Summary Glucocorticoid use in Duchenne and Becker muscular dystrophy prolongs ambulation but cause significant skeletal toxicity. Our analysis has immediate clinical implications, suggesting that growth hormone and testosterone have a stronger effect prior to first and subsequent vertebral fracture, respectively, relative to bisphosphonates alone in children with dystrophinopathies on chronic glucocorticoids. Purpose Glucocorticoids prolong ambulation in boys with Duchenne muscular dystrophy; however, they have significant endocrine side effects. We assessed the impact of growth hormone (GH), testosterone, and/or zoledronic acid (ZA) on vertebral fracture (VF) incidence in patients with dystrophinopathies on chronic glucocorticoids. Methods We conducted a longitudinal retrospective review of 27 males with muscular dystrophy. Accelerated failure time (AFT) models were used to estimate the relative time to VF while on GH, testosterone, and/or ZA compared to ZA alone. Results are reported as failure time ratio, where >1 indicates prolonged time versus PPPP=0.033). Conclusion GH and testosterone each decreased VF risk in patients independent of or in combination with ZA, respectively.


  • Open Access

    Case Report: Safety and Efficacy of Denosumab in Four Children With Noonan Syndrome With Multiple Giant Cell Lesions of the Jaw

    by Kristen Ferriero, Biraj Shah, Yun Yan, Surya Khatri, John Caccamese, Joseph A. Napoli, Michael B. Bober, Janet L. Crane

    Noonan syndrome is a genetic disorder caused by mutations in the RAS/MAPK pathway. Multiple giant cell lesions are a rare sequelae of disruptions in this pathway, termed Noonan-like multiple giant cell lesions (NL/MGCLs). Medical management of these tumors rather than surgical intervention is preferential as the lesions are benign but locally destructive and recurring. This case series describes four male pediatric patients with Noonan syndrome and multiple giant cell lesions of the jaw treated with denosumab, a monoclonal antibody to receptor activator of nuclear factor kappa B ligand (RANKL), which has been approved for the treatment of malignant giant cell tumors in adults but not evaluated for safety or efficacy in children. All four pediatric patients responded clinically and radiographically to the treatment. Adverse events occurred in a predictable pattern and included hypocalcemia and joint pain during the initiation of treatment and symptomatic hypercalcemia after the cessation of treatment. Growth was not significantly impaired in these skeletally immature patients. This case series demonstrates how a weight-adjusted denosumab dose can effectively treat NL/MGCLs and provides laboratory data for consideration of the timing of monitoring for known side effects.